ACADIA PHARMACEUTICALS INC (ACAD) research
ACADIA PHARMACEUTICALS INC- Sector
- Biotechnology
- Last price
- $20.11
- As of
Kresmion compiles this page from ACAD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ACADIA PHARMACEUTICALS INC (ACAD): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-24.
As of . Source: SEC EDGAR filings for ACAD. Method and limitations.
Share the ACAD intelligence card
See the full ACAD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ACAD on one page. Preview it with sample data, then open it live with a free account.
Preview the ACAD dossierActive signals for ACAD
- highCONSENSUS_BUY
3 tracked funds increased ACAD this 2026Q2, institutional consensus
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 207.2%, EPS $0.18 vs $0.0586 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +212% to ACAD (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +8293% to ACAD (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +17660% to ACAD (2026Q2)
FREE, NO ACCOUNT
Every signal on ACAD, as it fires
You are seeing 5 of 13 signals recorded on ACAD since 2026-05-16.
The five above landed across 3 days. The other 8 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ACAD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 004225108 · 2026Q2 | $61.6M | 0.07% | , |
| CITADEL ADVISORS LLCCUSIP 004225108 · 2026Q2 | $55.2M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 004225108 · 2026Q2 | $43M | 0.02% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 004225108 · 2026Q2 | $32.4M | 0.04% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 004225108 · 2026Q2 | $23.5M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 004225108 · 2026Q2 | $14.9M | 0.01% | , |
| Bridgewater Associates, LPCUSIP 004225108 · 2026Q2 | $1.3M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ACAD
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
ACAD against its peers
ACAD's operating margin of 9.8% ranks in the 84th percentile of 15 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ACAD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.1B USD | 33.0M USD | 97 | 17 |
| Operating margin | 9.8% | -178.4% | 84 | 15 |
| Net margin | 36.5% | -162.9% | 97 | 15 |
| Return on equity | 31.9% | -29.8% | 94 | 23 |
| P / E | 8.7x | n/a | n/a | 1 |
Peers (23): ARQT, XENE, GRTX, ELVN, DNLI, IDYA, VCYT, RCUS, CPRX, RLAY, CELC, LEGN, TLX, DYN, TNGX, VKTX, ZLAB, NAMS, PGEN, EWTX, MBX, ATAI, QURE. Left out: PBLS (no annual filing), ZLDPF (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ACAD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ACAD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ACAD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.